CDE

CDE refers to the public listing mAIntained by China's Center for Drug evaluation, a division of the national drug regulator. It is a searchable reference page rather than a Generative AI product, and it exists so that researchers, sponsors and analysts can check which drug candidates have been granted breakthrough therapy designation. The page is hosted on the agency's official website and is offered without charge.

What it does

The page presents official designation records in a browsable list fORMat. Visitors can look up whether a specific therapy APPears in the breakthrough designation program, review the listed Information for each entry, and follow the progression of designations over time. Because the content originates with the regulator, it functions as a primary source rather than a SECondary aggregator.

Key capabilities

• Public access to breakthrough therapy designation listings published by the drug eValuation authority.
• Lookup of indiVidual drugs and their listed designation information.
• Chronological review of designations to track regulatory ACTivity.
• Official agency sourcing, which supports citation in research and due diligence work.
• No account or payment requirement for bASIc browsing.

Who it is for

The listing is most relevant to pharmaceutical researchers, regulatory affairs staff, CLInical development teams, investors tracking pipelines, and journalists or analysts covering drug approvals. Academic groups studying regulatory pathways may also find it useful when compiling designation histories. General consumers looking for treatment guidance are better served by clinical Professionals, since the page is a regulatory record and not medical advice.

How to get started

Open the official page in a browser and use the on-page list to browse entries. Because the interface is in Chinese and organized as a conventional regulatory listing, users unfamiliar with the system may need to learn the terminology for designation types and review the column structure before searching. Keeping a record of the date you accessed a listing is helpful, as regulatory pages are updated periodically and past entries may be revised or reorganized.

Pricing and access caveat

Access appears to be free and open, though this may change and should be confirmed on the site itself. Availability can vary, and the page may load slowly or become interMITtently unavailable during peak demand. translation tools can help with non-Chinese readers, but translated wording may differ from the official terms, so verify important details against the original page. No veRSIon number, release schedule or fee structure is stated here because those details are not confirmed.